Table 3. Major Characteristics of Fifteen Controlled Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) versus Surgery alone with Systemic Chemotherapy (SC) and/or Early Postoperative Intraperitoneal Chemotherapy (EPIC).
| Author/ Year/ Country | Participating Institutions |
Study Period | Design | Level of Evidence | Number of CRC PC | Treatment strategy | |
|---|---|---|---|---|---|---|---|
| HIPEC group | Control group | ||||||
| Elias D/ 2010/ France [14] | 25 (a central database) |
1990-2007 | retrospective | IIa | 523 (523/523) | CRS+HIPEC with/without SC 443 pts CRS+HIPEC+EPIC with/without SC 9 pts HIPEC: 1. MMC (30-50 mg/m2) ± DDP (50-100 mg/m2) during 60 to 120min at 41°C using Coliseum or closed abdomen technique; 2. L-OHP (360-460 mg/m2)±CPT-11 (200 mg/m2) +intravenous 5-FU and LV during 30 minutes at 43°C using Coliseum or closed abdomen technique. EPIC: MMC (10 g/m2) on Day 1+5-FU (600 mg/m2) form Day 2 to Day 6 lasted 23 h SC: not reported the detailed regimen |
CRS+EPIC with/without SC 84 pts EPIC: MMC (10 g/m2) on Day 1+5-FU (600 mg/m2) form Day 2 to Day 6 lasted 23 h SC: not reported the detailed regimen No HIPEC |
| Esquivel J/ 2014 / America [29] |
21 (The American Society of Peritoneal Surface Malignancies (ASPSM)) |
1985-2012 | retrospective | IIa | 1,013 (1,013/1,013) | CRS+HIPEC 705 pts HIPEC: The chemotherapy drugs L-OHP or MMC or others but not reported the remaining details. SC (not detailed reported) No EPIC |
SC alone 308 pts SC (not detailed reported) No EPIC No HIPEC |
| Franko J/ 2010/ America [37] |
3 (one centre conducted HIPEC, two centre as a control) |
2001-2007 | retrospective | IIa | 105 (105/105) | CRS+HIPEC+SC 67 pts HIPEC: MMC 30mg for the first hour, followed by an additional 10 mg for 40 more minutes using the closed abdomen technique. (Perfusion fluid temperature not reported) No EPIC SC: 1. 5-FU and CPT-11; 2. L-OHP or biological agents (BEV and/or C225) |
Surgery + SC 38 pts SC: 1. 5-FU and CPT-11; 2. L-OHP or biological agents (BEV and/or C225) No EPIC No HIPEC |
Note: CRC: colorectal cancer; PC: peritoneal carcinomatosis; Pts: patients; MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; Cap: capecitabine; C225: cetuximab; CPT: camptothecin; BEV: bevacizumab; DXL: docetaxel; CBP: carboplatin; PAN: panitumumab;